Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) Other Non Operating Income: 2020-2025

Historic Other Non Operating Income for Caribou Biosciences (CRBU) over the last 6 years, with Sep 2025 value amounting to $1.9 million.

  • Caribou Biosciences' Other Non Operating Income fell 50.19% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.8 million, marking a year-over-year decrease of 42.48%. This contributed to the annual value of $15.3 million for FY2024, which is 0.79% down from last year.
  • Per Caribou Biosciences' latest filing, its Other Non Operating Income stood at $1.9 million for Q3 2025, which was down 15.32% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Other Non Operating Income ranged from a high of $4.8 million in Q4 2023 and a low of $16,000 during Q1 2021.
  • Over the past 3 years, Caribou Biosciences' median Other Non Operating Income value was $3.2 million (recorded in 2024), while the average stood at $3.4 million.
  • Per our database at Business Quant, Caribou Biosciences' Other Non Operating Income skyrocketed by 3,157.78% in 2022 and then plummeted by 50.19% in 2025.
  • Over the past 5 years, Caribou Biosciences' Other Non Operating Income (Quarterly) stood at $45,000 in 2021, then surged by 3,157.78% to $2.3 million in 2022, then spiked by 106.61% to $4.8 million in 2023, then crashed by 34.47% to $3.2 million in 2024, then plummeted by 50.19% to $1.9 million in 2025.
  • Its Other Non Operating Income was $1.9 million in Q3 2025, compared to $2.2 million in Q2 2025 and $2.6 million in Q1 2025.